DiaMedica Therapeutics Inc. (DMAC)
Largest Insider Buys in Sector
DMAC Stock Price History Chart
DMAC Stock Performance
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Insider Activity of DiaMedica Therapeutics Inc.
Over the last 12 months, insiders at DiaMedica Therapeutics Inc. have bought $49,200 and sold $0 worth of DiaMedica Therapeutics Inc. stock.
On average, over the past 5 years, insiders at DiaMedica Therapeutics Inc. have bought $2.22M and sold $3.53M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Wambeke David J. (Chief Business Officer) — $49,200.
The last purchase of 20,000 shares for transaction amount of $49,200 was made by Wambeke David J. (Chief Business Officer) on 2023‑11‑16.
List of Insider Buy and Sell Transactions, DiaMedica Therapeutics Inc.
| 2023-11-16 | Wambeke David J. | Chief Business Officer | 20,000 0.0542% | $2.46 | $49,200 | +17.99% | ||
| 2023-06-23 | Von Koch Thomas | 10 percent owner | 1.47M 4.4481% | $3.40 | $5M | -33.18% | ||
| 2023-06-23 | Wambeke David J. | Chief Business Officer | 38,364 0.1334% | $3.91 | $150,003 | -33.18% | ||
| 2023-06-23 | Giuffre Randall Michael | director | 65,000 0.2261% | $3.91 | $254,150 | -33.18% | ||
| 2023-06-23 | Pilnik Richard D. | director | 38,363 0.1334% | $3.91 | $149,999 | -33.18% | ||
| 2023-06-23 | Pauls Dietrich John | President and CEO | 12,787 0.0445% | $3.91 | $49,997 | -33.18% | ||
| 2023-06-23 | Kellen Scott | CFO and Secretary | 10,000 0.0348% | $3.91 | $39,100 | -33.18% | ||
| 2023-06-23 | Semba Charles Pauling | director | 12,787 0.0445% | $3.91 | $49,997 | -33.18% | ||
| 2023-04-10 | Wambeke David J. | Chief Business Officer | 468,750 1.8065% | $1.60 | $750,000 | +79.62% | ||
| 2022-12-09 | Giuffre Randall Michael | director | 37,079 0.1402% | $1.43 | $53,023 | +57.34% | ||
| 2022-12-08 | Giuffre Randall Michael | director | 20,000 0.0735% | $1.40 | $28,000 | +55.90% | ||
| 2022-12-07 | Giuffre Randall Michael | director | 22,574 0.086% | $1.40 | $31,604 | +61.15% | ||
| 2022-12-06 | Giuffre Randall Michael | director | 2,300 0.0083% | $1.35 | $3,105 | +57.39% | ||
| 2022-12-05 | Pilnik Richard D. | director | 35,000 0.14% | $1.39 | $48,493 | +69.08% | ||
| 2022-12-02 | Sale | Von Koch Thomas | director | 2.86M 9.0121% | $1.24 | $3.53M | +47.97% | |
| 2022-12-02 | Von Koch Thomas | director | 2.86M 9.0121% | $1.24 | $3.53M | +47.97% | ||
| 2022-12-01 | Giuffre Randall Michael | director | 46,952 0.1775% | $1.20 | $56,334 | +82.08% | ||
| 2022-11-30 | Giuffre Randall Michael | director | 2,970 0.0112% | $1.19 | $3,534 | +82.77% | ||
| 2022-11-29 | Giuffre Randall Michael | director | 18,125 0.068% | $1.19 | $21,569 | +80.00% | ||
| 2022-11-16 | Pauls Dietrich John | President and CEO | 20,000 0.0756% | $1.21 | $24,200 | +71.07% |
Insider Historical Profitability
| Wambeke David J. | Chief Business Officer | 527114 1.3888% | $2.96 | 3 | 0 | +23.22% |
| Von Koch Thomas | 10 percent owner | 4326435 11.3992% | $2.96 | 2 | 1 | +7.4% |
| TomEnterprise AB | 2855827 7.5245% | $2.96 | 1 | 0 | +16.67% | |
| Giuffre Randall Michael | director | 360355 0.9495% | $2.96 | 10 | 0 | +49.77% |
| Pilnik Richard D. | director | 248245 0.6541% | $2.96 | 7 | 0 | +16.67% |
| Pauls Dietrich John | President and CEO | 68591 0.1807% | $2.96 | 5 | 0 | +13.96% |
| Burroughs Amy L. | director | 44950 0.1184% | $2.96 | 1 | 0 | <0.0001% |
| ALCORN HARRY W JR | SVP, Clinical Operations | 43582 0.1148% | $2.96 | 5 | 0 | <0.0001% |
| Kellen Scott | CFO and Secretary | 32290 0.0851% | $2.96 | 6 | 0 | +15.37% |
| Semba Charles Pauling | director | 29943 0.0789% | $2.96 | 1 | 0 | <0.0001% |
| Xiao Zhenyu | 7100 0.0187% | $2.96 | 1 | 0 | <0.0001% | |
| Parsons James T. | director | 6100 0.0161% | $2.96 | 1 | 0 | <0.0001% |
| Verdoorn Todd A. | Chief Scientific Officer | 2000 0.0053% | $2.96 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| The Vanguard Group | $2.81M | 2.67 | 1.01M | +26.35% | +$585,442.28 | <0.0001 | |
| Leon G. Cooperman | $2.45M | 2.33 | 883,623 | 0% | +$0 | 0.1 | |
| First Manhattan Co. | $2.35M | 2.24 | 850,038 | +640.81% | +$2.04M | 0.01 | |
| Paragon Associates Paragon Associates Ii Joint Venture | $1.39M | 1.32 | 500,000 | 0% | +$0 | 2.47 | |
| Geode Capital Management | $662,841.00 | 0.63 | 239,235 | +9.35% | +$56,679.58 | <0.0001 | |
| Bleichroeder Lp | $615,818.00 | 0.59 | 222,317 | 0% | +$0 | 0.16 | |
| Susquehanna International Group | $579,850.00 | 0.55 | 209,332 | +657.93% | +$503,345.32 | <0.01 | |
| Northern Trust | $354,059.00 | 0.34 | 127,819 | -4.35% | -$16,104.80 | <0.0001 | |
| Aristides Capital | $294,542.00 | 0.28 | 106,333 | 0% | +$0 | 0.13 | |
| BlackRock | $286,334.00 | 0.27 | 103,370 | -1.3% | -$3,772.73 | <0.0001 | |
| Morgan Stanley | $253,657.00 | 0.24 | 91,573 | -24.32% | -$81,498.87 | <0.0001 | |
| State Street | $184,562.00 | 0.18 | 66,629 | 0% | +$0 | <0.0001 | |
| Catalyst Financial Partners Llc | $94,294.00 | 0.1 | 36,267 | 0% | +$0 | 0.02 | |
| Citadel Advisors LLC | $66,535.00 | 0.06 | 24,020 | +5.75% | +$3,614.83 | <0.0001 | |
| BNY Mellon | $66,479.00 | 0.06 | 24,000 | -29.89% | -$28,344.98 | <0.0001 | |
| Stonebridge Capital Advisors Llc | $55,400.00 | 0.05 | 20,000 | 0% | +$0 | 0.01 | |
| Dimensional Fund Advisors | $46,977.00 | 0.05 | 16,959 | 0% | +$0 | <0.0001 | |
| Jane Street Capital | $42,209.00 | 0.04 | 15,238 | -35.87% | -$23,608.56 | <0.0001 | |
| Charles Schwab | $36,705.00 | 0.04 | 13,251 | 0% | +$0 | <0.0001 | |
| Massmutual Trust Co Fsb Adv | $13,362.00 | 0.01 | 4,824 | 0% | +$0 | <0.0001 | |
| U.S. Bancorp | $12,008.00 | 0.01 | 4,335 | 0% | +$0 | <0.0001 | |
| Tower Research Capital | $7,468.00 | 0.01 | 2,696 | -62.88% | -$12,653.50 | <0.0001 | |
| UBS | $5,335.00 | 0.01 | 1,926 | New | +$5,335.00 | <0.0001 | |
| Legend Financial Advisors Inc | $2,770.00 | <0.01 | 1,000 | 0% | +$0 | <0.01 | |
| Advisor Group Holdings Inc | $2,770.00 | <0.01 | 1,000 | 0% | +$0 | <0.0001 | |
| Royal Bank of Canada | $2,000.00 | <0.01 | 845 | -21.9% | -$560.95 | <0.0001 | |
| Toronto-Dominion Bank | $66.00 | <0.01 | 24 | 0% | +$0 | <0.0001 | |
| Wells Fargo | $485.00 | <0.01 | 175 | +1.74% | +$8.31 | <0.0001 |